Clin2
NCT06841172Possibly a fitRecruiting

Radiation vs treatment switch for limited liver cancer growth

OligoProgressive Metastatic DiseaseHepatocellular Carcinoma (HCC)RadiotherapySystemic Therapy

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests whether giving radiation to a few growing cancer spots while continuing your current treatment works better than switching to a new treatment right away. It's for people whose advanced liver cancer has only barely started to progress on their first therapy.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
132 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must have advanced liver cancer (HCC) that has spread beyond the liver.
  • While on your first treatment, only a small number of cancer spots (1 to 5) in up to 3 body areas have started to grow.
  • Your cancer must have been stable (no growth) for at least 3 months before this limited growth happened.
  • The growing spots must be treatable with radiation therapy and you must be able to have a CT scan or MRI to check your cancer.
  • You must be between 18 and 75 years old, in good general health, and have good liver function.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06870942Recruiting· Phase 2
Radiation therapy for liver cancer that progresses after first immunotherapy

This trial tests whether adding targeted radiation to liver cancer patients who have limited progression after initial immunotherapy can help control the disease. It is for people with hepatocellular carcinoma (HCC) whose cancer has started to grow in just a few spots after their first PD-1 treatment.

Shanghai, Shanghai Municipality
NCT06367972Recruiting· Phase 2/Phase 3
Extending systemic therapy with local treatment for limited cancer growth

This trial tests whether adding local treatments like radiation or surgery to standard therapy can help control cancer that has started to grow in just a few spots. It is for people with certain advanced cancers that have 1 to 5 growing lesions that can be treated locally.

Houston, Texas
NCT06918951Recruiting
Stereotactic radiation vs standard radiation for limited cancer spread

This trial compares two types of radiation for people whose cancer has spread to a few new spots while on or after treatment. It tests whether a precise, high-dose radiation approach (stereotactic) works better than the usual palliative radiation for controlling these growing spots.

Surrey, British Columbia
NCT06813664Not yet recruiting· Phase 2
Targeted radiation for lung cancer that's spreading

This study tests whether adding targeted radiation to your current lung cancer pill can help control areas where the cancer has started to grow again. It may help you delay needing to switch treatments.

Toronto, Ontario
NCT06925984Recruiting
Targeted radiation for breast cancer that has spread and is growing a little

This trial tests whether giving focused, high-dose radiation to spots where the cancer is growing can help control the disease while you stay on your current hormone therapy and/or CDK4/6 inhibitor. It is for people with ER+/HER2- breast cancer that has spread to a few places and is slowly starting to progress.

Brussels
NCT07293468Recruiting· Phase 2/Phase 3
Comparing two treatments for advanced liver cancer

This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).

Hong Kong

Hear when a new OligoProgressive Metastatic Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.